We’re proud to announce that a Fortune 500 pharmaceutical leader has officially gone live with ReTrans, our AI-driven literature surveillance platform. This milestone not only reinforces the growing global trust in ALWIS Group’s technological innovations but also showcases the scalability, compliance, and efficiency of ReTrans in enterprise pharmacovigilance environments. As regulatory expectations grow, ReTrans is empowering major pharma organizations to streamline their safety operations with confidence and agility.

• Successful Global Implementation of ReTrans by a Fortune 500 pharmaceutical company.

• AI-powered literature monitoring with enhanced accuracy, speed, and regulatory compliance.

• Seamless integration with existing PV infrastructure and workflows.

• Enabled real-time surveillance across global scientific literature databases.

• Further validation of ALWIS Group’s leadership in pharmacovigilance technology.

• Strengthens our mission to drive safer, faster, and smarter drug safety outcomes.